ERBB4 and renal fibrosis: Among them, we demonstrated that targeting Erbb4-IR may represent a novel therapy for inhibiting progression of renal fibrosis (Feng et al., 2018; Sun et al., 2018), whereas Arid-IR may related to the renal inflammation (Zhou et al., 2015).